Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy

Molecular Oncology

Volumn 6, Issue 1, 2012, Pages 1-14

  Proietti, Enrico ^a   Moschella, Federica ^a   Capone, Imerio ^a   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; Chemotherapy; Clinical trials; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; TEMOZOLOMIDE;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL FUNCTION; DENDRITIC CELL; HOMEOSTASIS; HUMAN; HYPOTHESIS; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR IMMUNITY;

EID: 84856301759     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.11.005     Document Type: Review

References (110)

1. Adair S.J., Hogan K.T. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. Immunother. 2009, 58:589-601.
2. Apetoh L., Ghiringhelli F., Tesniere A., Criollo A., Ortiz C., Lidereau R., et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 2007, 220:47-59.
3. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
4. Asavaroengchai W., Kotera Y., Mule J.J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. U S A 2002, 99:931-936.
5. Berenblum I. The modifying influence of dychloroethyl sulphide on the induction of tumours in mice by tar. J. Pathol. Bacteriol. 1929, 32:424-434.
6. Berendt M.J., North R.J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 1980, 151:69-80.
7. Biragyn A., Ruffini P.A., Leifer C.A., Klyushnenkova E., Shakhov A., Chertov O., et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002, 298:1025-1029.
8. Bracci L., Moschella F., Sestili P., La Sorsa V., Valentini M., Canini I., et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 2007, 13:644-653.
9. Braun D.P., Harris J.E. Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: correlation with rebound overshoot immune function recovery. Clin. Immunol. Immunopathol. 1981, 20:193-214.
10. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, (Epub ahead of print).
11. Calabrese E.J. Hormetic dose-response relationships in immunology: occurrence, quantitative features of the dose response, mechanistic foundations, and clinical implications. Crit. Rev. Toxicol. 2005, 35:89-295.
12. Calabrese E.J., Bachmann K.A., Bailer A.J., Bolger P.M., Borak J., Cai L., et al. Biological stress response terminology: integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol. Appl. Pharmacol. 2007, 222:122-128.
13. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 2005, 202:1691-1701.
14. Cheever M.A., Greenberg P.D., Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 1980, 125:711-714.
15. Chopra A., Kim T.S., InSug O.S., Martinez D., Cohen E.P. Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. Int. J. Cancer 2006, 118:2888-2898.
16. Chu Y., Wang L.X., Yang G., Ross H.J., Urba W.J., Prell R., et al. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J. Immunother. 2006, 29:367-380.
17. Coral S., Sigalotti L., Altomonte M., Engelsberg A., Colizzi F., Cattarossi I., et al. 5-Aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res. 2002, 8:2690-2695.
18. Correale P., Botta C., Cusi M., Del Vecchio M., De Santi M., Gori Savellini G., et al. Cetuximab+/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response invitro. Int. J. Cancer 2011, (Epub ahead of print).
19. Dempke W., Von Poblozki A., Grothey A., Schmoll H.J. Human hematopoietic growth factors: old lessons and new perspectives. Anticancer Res. 2000, 20:5155-5164.
20. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49-59.
21. Ding Z.C., Blazar B.R., Mellor A.L., Munn D.H., Zhou G. Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 2010, 115:2397-2406.
22. Dummer W., Niethammer A.G., Baccala R., Lawson B.R., Wagner N., Reisfeld R.A., et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 2002, 110:185-192.
23. Emens L.A. Chemoimmunotherapy. Cancer J. 2010, 16:295-303.
24. Ercolini A.M., Ladle B.H., Manning E.A., Pfannenstiel L.W., Armstrong T.D., Machiels J.P., et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 2005, 201:1591-1602.
25. Essers M.A., Offner S., Blanco-Bose W.E., Waibler Z., Kalinke U., Duchosal M.A., et al. IFNalpha activates dormant haematopoietic stem cells invivo. Nature 2009, 458:904-908.
26. Fadul C.E., Fisher J.L., Hampton T.H., Lallana E.C., Li Z., Gui J., et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J. Immunother. 2011, 34:382-389.
27. Fonsatti E., Nicolay H.J., Sigalotti L., Calabro L., Pezzani L., Colizzi F., et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res. 2007, 13:3333-3338.
28. Freitas A.A., Agenes F., Coutinho G.C. Cellular competition modulates survival and selection of CD8+ T cells. Eur. J. Immunol. 1996, 26:2640-2649.
29. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
30. Gattinoni L., Finkelstein S.E., Klebanoff C.A., Antony P.A., Palmer D.C., Spiess P.J., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
31. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., et al. Acquisition of full effector function invitro paradoxically impairs the invivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 2005, 115:1616-1626.
32. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336-344.
33. Ghiringhelli F., Menard C., Martin F., Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 2006, 214:229-238.
34. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56:641-648.
35. Gilman A., Philips F.S. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 1946, 103:409-415.
36. Greenberg P.D., Cheever M.A., Fefer A. Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res. 1980, 40:4428-4432.
37. Greenberg P.D., Kern D.E., Cheever M.A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 1985, 161:1122-1134.
38. Gringhuis S.I., den Dunnen J., Litjens M., van der Vlist M., Wevers B., Bruijns S.C., et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat. Immunol. 2009, 10:203-213.
39. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 2001, 193:1285-1294.
40. Kaneno R., Shurin G.V., Tourkova I.L., Shurin M.R. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl. Med. 2009, 7:58.
41. Kasprowicz D.J., Droin N., Soper D.M., Ramsdell F., Green D.R., Ziegler S.F. Dynamic regulation of FoxP3 expression controls the balance between CD4+ T cell activation and cell death. Eur. J. Immunol. 2005, 35:3424-3432.
42. Klebanoff C.A., Gattinoni L., Palmer D.C., Muranski P., Ji Y., Hinrichs C.S., et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 2011, 17:5343-5352.
43. Klechevsky E., Flamar A.L., Cao Y., Blanck J.P., Liu M., O'Bar A., et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010, 116:1685-1697.
44. Le H.K., Graham L., Cha E., Morales J.K., Manjili M.H., Bear H.D. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 2009, 9:900-909.
45. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Schlom J., Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
46. Machiels J.P., Reilly R.T., Emens L.A., Ercolini A.M., Lei R.Y., Weintraub D., et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001, 61:3689-3697.
47. Mackall C.L., Hakim F.T., Gress R.E. Restoration of T-cell homeostasis after T-cell depletion. Semin. Immunol. 1997, 9:339-346.
48. Maguire H.C., Ettore V.L. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J. Invest. Dermatol. 1967, 48:39-43.
49. Maine G.N., Mule J.J. Making room for T cells. J. Clin. Invest. 2002, 110:157-159.
50. Malvicini M., Ingolotti M., Piccioni F., Garcia M., Bayo J., Atorrasagasti C., et al. Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Mol. Oncol. 2011, 5:242-255.
51. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
52. Matar P., Rozados V.R., Gervasoni S.I., Scharovsky G.O. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol. Immunother. 2002, 50:588-596.
53. Meerveld-Eggink A., de Weerdt O., van der Velden A.M., Los M., van der Velden A.W., Stouthard J.M., et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann. Oncol. 2011, 22:2031-2035.
54. Montero E., Valdes M., Avellanet J., Lopez A., Perez R., Lage A. Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. Vaccine 2009, 27:2230-2239.
55. Moschella F., Proietti E., Capone I., Belardelli F. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann. N. Y. Acad. Sci. 2010, 1194:169-178.
56. Moschella F., Valentini M., Arico E., Macchia I., Sestili P., D'Urso M.T., et al. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res. 2011, 71:3528-3539.
57. Nakahara T., Uchi H., Lesokhin A.M., Avogadri F., Rizzuto G.A., Hirschhorn-Cymerman D., et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010, 115:4384-4392.
58. Natsume A., Wakabayashi T., Tsujimura K., Shimato S., Ito M., Kuzushima K., et al. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int. J. Cancer 2008, 122:2542-2553.
59. Nauta A.J., Raaschou-Jensen N., Roos A., Daha M.R., Madsen H.O., Borrias-Essers M.C., et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur. J. Immunol. 2003, 33:2853-2863.
60. Nistico P., Capone I., Palermo B., Del Bello D., Ferraresi V., Moschella F., et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer 2009, 124:130-139.
61. Nizar S., Copier J., Meyer B., Bodman-Smith M., Galustian C., Kumar D., et al. T-regulatory cell modulation: the future of cancer immunotherapy?. Br. J. Cancer 2009, 100:1697-1703.
62. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982, 155:1063-1074.
63. Obeid M., Panaretakis T., Joza N., Tufi R., Tesniere A., van Endert P., et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007, 14:1848-1850.
64. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
65. Ogden C.A., deCathelineau A., Hoffmann P.R., Bratton D., Ghebrehiwet B., Fadok V.A., et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J. Exp. Med. 2001, 194:781-795.
66. Palermo B., Del Bello D., Sottini A., Serana F., Ghidini C., Gualtieri N., et al. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res. 2010, 70:7084-7092.
67. Pfannenstiel L.W., Lam S.S., Emens L.A., Jaffee E.M., Armstrong T.D. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol. 2010, 263:79-87.
68. Powell D.J., de Vries C.R., Allen T., Ahmadzadeh M., Rosenberg S.A. Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J. Immunother. 2007, 30:438-447.
69. Proietti E., Greco G., Garrone B., Baccarini S., Mauri C., Venditti M., et al. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 1998, 101:429-441.
70. Proietti E., Tritarelli E., Gabriele L., Testa U., Greco G., Pelosi E., et al. Combined interleukin 1 beta/interleukin 2 treatment in mice: synergistic myelostimulatory activity and protection against cyclophosphamide-induced myelosuppression. Cancer Res. 1993, 53:569-576.
71. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H.I., Antonia S., et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010, 120:1111-1124.
72. Rizza P., Capone I., Moretti F., Proietti E., Belardelli F. IFN-alpha as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. Expert Rev. Vaccines 2011, 10:487-498.
73. Robinson M.J., Osorio F., Rosas M., Freitas R.P., Schweighoffer E., Gross O., et al. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J. Exp. Med. 2009, 206:2037-2051.
74. Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321.
75. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
76. Roux S., Apetoh L., Chalmin F., Ladoire S., Mignot G., Puig P.E., et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J. Clin. Invest. 2008, 118:3751-3761.
77. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
78. Salem M.L., Al-Khami A.A., El-Naggar S.A., Diaz-Montero C.M., Chen Y., Cole D.J. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J. Immunol. 2010, 184:1737-1747.
79. Salem M.L., Diaz-Montero C.M., Al-Khami A.A., El-Naggar S.A., Naga O., Montero A.J., et al. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses invivo when stimulated with the TLR3 agonist poly(I: C). J. Immunol. 2009, 182:2030-2040.
80. Salem M.L., Kadima A.N., El-Naggar S.A., Rubinstein M.P., Chen Y., Gillanders W.E., et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 2007, 30:40-53.
81. Sampson J.H., Aldape K.D., Archer G.E., Coan A., Desjardins A., Friedman A.H., et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011, 13:324-333.
82. Schiavoni G., Mattei F., Di Pucchio T., Santini S.M., Bracci L., Belardelli F., et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000, 95:2024-2030.
83. Schiavoni G., Sistigu A., Valentini M., Mattei F., Sestili P., Spadaro F., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011, 71:768-778.
84. Schluns K.S., Kieper W.C., Jameson S.C., Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells invivo. Nat. Immunol. 2000, 1:426-432.
85. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006, 203:1693-1700.
86. Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., DeMarzo A.M., et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 2008, 14:3254-3261.
87. Shurin G.V., Tourkova I.L., Kaneno R., Shurin M.R. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J. Immunol. 2009, 183:137-144.
88. Sistigu A., Viaud S., Chaput N., Bracci L., Proietti E., Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 2011, 33:369-383.
89. Sojka D.K., Donepudi M., Bluestone J.A., Mokyr M.B. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J. Immunol. 2000, 164:6230-6236.
90. Stephens L.A., Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J. Immunol. 2000, 165:3105-3110.
91. Terme M., Chaput N., Combadiere B., Ma A., Ohteki T., Zitvogel L. Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J. Immunol. 2008, 180:4679-4686.
92. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
93. Torelli G.F., Natalino F., Barberi W., Maggio R., Peragine N., De Propris M.S., et al. Clinical responses in allografted acute leukaemia patients with resistant disease using a combined chemo-immunotherapeutic treatment strategy. Br. J. Haematol. 2010, 151:86-89.
94. Tseng C.W., Hung C.F., Alvarez R.D., Trimble C., Huh W.K., Kim D., et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin. Cancer Res. 2008, 14:3185-3192.
95. Vadlamudi S., Padarathsingh M., Bonmassar E., Goldin A. Effect of combination treatment with cyclophosphamide and isogeneic or allogeneic spleen and bone marrow cells in leukemic (L1210) mice. Int. J. Cancer 1971, 7:160-166.
96. van der Most R.G., Currie A.J., Cleaver A.L., Salmons J., Nowak A.K., Mahendran S., et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009, 4:e6982.
97. Vereecque R., Saudemont A., Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 2004, 18:1223-1230.
98. Viaud S., Flament C., Zoubir M., Pautier P., Lecesne A., Ribrag V., et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011, 71:661-665.
99. Vierboom M.P., Bos G.M., Ooms M., Offringa R., Melief C.J. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int. J. Cancer 2000, 87:253-260.
100. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70:3052-3061.
101. Weck M.M., Appel S., Werth D., Sinzger C., Bringmann A., Grunebach F., et al. hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood 2008, 111:4264-4272.
102. Wu Z., Bensinger S.J., Zhang J., Chen C., Yuan X., Huang X., et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat. Med. 2004, 10:87-92.
103. Yang S., Haluska F.G. Treatment of melanoma with 5-fluorouracil or dacarbazine invitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J. Immunol. 2004, 172:4599-4608.
104. Ye Z.J., Zhou Q., Gu Y.Y., Qin S.M., Ma W.L., Xin J.B., et al. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J. Immunol. 2010, 185:6348-6354.
105. Zaragoza B., Evaristo C., Kissenpfennig A., Libri V., Malissen B., Rocha B., et al. Cell-to-cell interactions and signals involved in the reconstitution of peripheral CD8 T(CM) and T(EM) cell pools. PLoS One 2011, 6:e17423.
106. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 2005, 201:139-148.
107. Zhang X., Sun S., Hwang I., Tough D.F., Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells invivo by IL-15. Immunity 1998, 8:591-599.
108. Zhang Y.L., Li J., Mo H.Y., Qiu F., Zheng L.M., Qian C.N., et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol. Cancer 2010, 9:4.
109. Zhong H., Han B., Tourkova I.L., Lokshin A., Rosenbloom A., Shurin M.R., et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin. Cancer Res. 2007, 13:5455-5462.
110. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.